Good medicine chemotherapy will not reduce the cost, slow delay control

Good medicine chemotherapy will not reduce the cost, slow delay control


The new program for eliminating doctors and Medicare medical clinics for the medication they buy for patients will not result in reduced costs and can lead to attention, according to producers.

The International Trade Agent Product, or IPI, announced Thursday that it will complement the Medicare system. Part B. CMS will contract with private vendors to purchase the drugs and distribute them to producers. In the past, doctors and clinical hospital carers paid for this purchase and calculated their own.

While CMS claims a new payment system that can lead to new competition and low cost through credit and credit discount, specialized professionals forbid that day.

Hospitals know that CMS is just about the product she wants after the company needs to know about the last summer, and they have doubts that it will lead to a significant change in in Medicare spendings.

There is no guarantee of what these vendors will do on new drugs, says Eric Lucas and Clara Evans, senior medical staff, who work with hospitals 39.

"We have no doubt that the third-party drug vendors can force more drug users to reduce the cost," Lucas and Evans said in a letter. "Sellers refuse to do so and buy on new drugs without any competition."

New advertisements in the product seek to be middle-aged who will increase the burden of administration in hospitals, says Steven Bernstetter, director of health policy and law at BJC HealthCare, St. Louis. IPI vendors use non-profit companies (PBMs) that use private companies, say it.

"An important driver of drug medications affects the increase in the number of subscribers who have nothing to do with good development, distribution or delivery of medical equipment from medical doctors," said Bernstetter.

But to bring the true price, Congress would need to log in and allow Medicare to trade with the professionals, he said.

Secretary HHS, Alex Azar, opposed this trend, which equaled "social science."

The CMS describes a new approach to the CAP (CAP) program that runs between 2006 and 2008, and sets up some oppositions & # 39; opposition to the program plan.

Like a new program, CMS under CAP has contracted with sellers to purchase parts B for producers.

The company used the product after it failed to finance or assisted consumers since the voluntary donation. Nearly 1,000 services were attended, according to federal information. He also attempted to find customers for the program. One businessman entered the protests.

The Center for the Rheumatology Institute of the United States urged CMS to reopen the system. It shows that researchers at CAP can not get the needed medications at the same time. Doctors in this demonstration have asked some specialist solutions from the vendor before receiving a patient visit.

"This limitates their ability to deal with illnesses or drugs in the face of adverse circumstances," said Dr. David Daikh, head of the US Rheumatology Institute, in a letter.

But Secretary HHS Alex Azar said the IPI system would not repeat the error again. IPIs will be necessary for applicants within 50 percent of the country, so it is best that the product will reduce the costs, he said.

"How can we expect doctors to be able to choose themselves to spend money on expensive drugs?" Azar said Friday at the time of the Brookings Commission appearance.

IPIs can be successful because there are products that have not been available over the past few years, said Kuo Tong, director of the Internet explorer.

"One of the problems with CAP is that time communication," Tong said. "This [model] is designed for a seller of Amazon which can compete, promote the port of advertisements and use of equipment. "

Healthcare services and services that want to monitor drug purchasing can maintain this power through the struggle for IPI ownership. They do not have this opportunity under CAP, according to Tong.

Sellers will be able to work with companies now that CMS will require hundreds of thousands of producers to work with them, said Fred Bentley, vice president of Avalere.

Participation can be a success for CMS sellers, but doctors say that the list for B sections does not want to be compelled to be compelled to participate in this program.

In 2006, Medicare B was initially paying 6% doctors on a wide range of drug sales. Under the IPI, doctors will be charged with non-priced drugs.

Doctors are concerned that they can lose the amount of revenue in this process.

"It can lead to significant decline in patient care if small and rural activities can not be part of a loan that can make money in the changes that can be paid," said Dr. Angus Worthing, president of the US Academy of Rheumatology. "In those cases, patients may be forced to receive medication in the most expensive settings or to stop the entire care plan."